Press Release: "Free to Breathe Partners With Antidote Technologies to Empower Patients to Find and Take Part in Lung Cancer Research"
MADISON, WI AND NEW YORK, NY (February 22, 2017) – Free to Breathe, a non-profit organization dedicated to finding a cure for lung cancer, and Antidote Technologies, a digital health company, today announced that they have teamed up to increase participation in lung cancer research. This partnership means that the Free to Breathe website now features Antidote’s unique clinical trial search tool, offering all patients and caregivers the opportunity to answer a few questions to find opportunities to take part in lung cancer research.
Just four percent of all cancer patients in the U.S. take part in clinical trials. This lack of participants means that four out of every five trials are delayed or closed. Medical progress is slowed, and patients continue to wait for answers. Lung cancer kills more Americans than any other cancer; patients and their loved ones have no time to waste.
Free to Breathe is made up of lung cancer survivors, advocates, researchers, healthcare professionals, and industry leaders, all of whom share in the organization’s mission to ensure that surviving lung cancer is the expectation, not the exception. They aim to double lung cancer survival by 2022, and one of the main pathways to achieving this ambitious goal is increasing the number of lung cancer patients participating in clinical trials. This is exactly why the organization is collaborating with Antidote, a digital health startup aiming to accelerate medical research, so the latest treatments in development can reach the people who need them, faster. Antidote Match is a search tool using technology with natural language processing and artificial intelligence to make it easier than ever before for people to find their best clinical trial matches. This tool is now available on the Free to Breathe website.
“For many years, there wasn’t very much good news for lung cancer patients – but the last two years have been banner years for lung cancer, with several new immunotherapy and targeted treatments approved. We’re excited to be offering hope to patients with lung cancer,” said Mary Henningfield, Ph.D., Director of Scientific Education and Research at Free to Breathe. “With that said, enrollment in lung cancer clinical trials in is still low, and one of the reasons is difficulty finding the right trial. Our partnership with Antidote will help change that for our community.”
“The work Free to Breathe is doing to connect patients to research opportunities is fantastic,” said Pablo Graiver, CEO at Antidote. “Now is a time we can build on the recent momentum we’ve seen in lung cancer research, and we’re honored to be working with Free to Breathe to ensure that patients living with lung cancer understand their research options and are able to take part.”
# # #
About Free to Breathe
Free to Breathe is a non-profit organization made up of lung cancer survivors, advocates, researchers, healthcare professionals, and industry leaders. They are united in the belief that every person with lung cancer deserves a cure. For more information, please visit www.freetobreathe.org.
Antidote is a digital health company on a mission. Their aim is to accelerate the breakthroughs of new treatments by bridging the gap between medical research and the people who need them.
In a world where 80% of clinical trials are delayed or closed due to lack of awareness, Antidote uses cutting-edge technology to match the right patients with the right trials, helping medical researchers make faster progress, and offering new treatment options to patients in need. Antidote was launched as TrialReach in 2010, and is based in the US and UK.
This is a global effort to advance healthcare for everyone. To find out how you can help shape medical history, visit http://www.antidote.me.